Cox enzyme inhibitor, celecoxib, reduces steatosis and liver lipogenesis in high-fat fed mice

Página do item simplificado
dc.creatorJamille Fernandes Lula
dc.creatorBruna Mara Aparecida de Carvalho Mesquita
dc.creatorLeandro de Freitas Teles
dc.creatorSérgio Henrique Sousa Santos
dc.creatorAlfredo Maurício Batista de Paula
dc.creatorAndré Luiz Sena Guimaraes
dc.creatorErivelton Pereira dos Santos
dc.creatorDeborah de Farias Lelis
dc.creatorLuís Paulo Oliveira
dc.creatorLucyana Conceição Farias
dc.creatorIgor Viana Brandi
dc.creatorKarla Nayara de Oliveira Santana
dc.date.accessioned2022-06-22T12:43:09Z
dc.date.accessioned2025-09-08T23:41:56Z
dc.date.available2022-06-22T12:43:09Z
dc.date.issued2017
dc.identifier.doihttp://doi.org/10.2174/1573408014666171220152537
dc.identifier.issn1875-6662
dc.identifier.urihttps://hdl.handle.net/1843/42592
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofCurrent Enzyme Inhibition
dc.rightsAcesso Restrito
dc.subjectAnalgésicos
dc.subjectEnzimas
dc.subjectInibidores enzimáticos
dc.subjectAgentes anti-inflamatórios
dc.subjectFígado gorduroso
dc.subjectObesidade
dc.titleCox enzyme inhibitor, celecoxib, reduces steatosis and liver lipogenesis in high-fat fed mice
dc.typeArtigo de periódico
local.citation.epage119
local.citation.issue2
local.citation.spage114
local.citation.volume14
local.description.resumoBackground: Obesity is an important risk factor for nonalcoholic fatty liver disease which varies from hepatic steatosis to liver cirrhosis. Interventions in weight and metabolic control are important in reducing steatosis risk. Aims: The aim of the present study was to investigate the role of celecoxib in hepatic triacylglycerol deposition in non-alcoholic fatty liver disease exploring the signaling involved in obese mice lipogenesis. Methods: Males FVB/N mice were allocated into three groups and were fed with experimental diets: standard, a high-fat diet or a high-fat diet along with Cox-2 inhibitor treatment (Celecoxib; 100mg/kg of body weight). The body weight, food intake, blood parameters and liver histology were analyzed. Expression of liver lipogenesis-related genes (ACC, PPAR-γ, FAS, SREBP-1c) was evaluated by quantitative real-time PCR. Results: The main findings showed that celecoxib treatment resulted in body weight loss in obese animals, reduced food consumption and decreased triglycerides. ACC, FAS and SREBP1-c mRNA expression was significantly suppressed in HFD+ICOX-2 fed mice. Conclusion: Celecoxib improved lipid metabolism and decreased fat deposition in the liver of obese mice by reducing lipogenesis, which may be a promising therapeutic target for liver disorders, obesity and its comorbidities.
local.identifier.orcidhttps://orcid.org/ 0000-0001-8980-8599
local.identifier.orcidhttps://orcid.org/0000-0001-6714-7996
local.publisher.countryBrasil
local.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS
local.publisher.initialsUFMG
local.url.externahttp://www.eurekaselect.com/article/87479

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG